Breaking Finance News

Zacks Investment Research upgraded Bio-Path Holdings Inc (NASDAQ:BPTH) to Hold in a report released today.

Just yesterday Bio-Path Holdings Inc (NASDAQ:BPTH) traded -9.91% lower at $1.00. BPTH’s 50-day average is $1.26 and its two hundred day average is $1.45. With the last stock price close down -30.83% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.05% over the same time. 313,580 shares of the stock were exchanged, up from an average trading volume of 136,795

Zacks Investment Research has upgraded Bio-Path Holdings Inc (NASDAQ:BPTH) to Hold in a report released on Wednesday January 11, 2017.

See Chart Below

Bio-Path Holdings Inc (NASDAQ:BPTH)

Bio-Path Holdings Inc has a 52 week low of $0.95 and a 52 week high of $3.19 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 1 firm has reported on the company. The average stock price target is $5.00 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Bio-Path Holdings Inc (NASDAQ:BPTH)

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *